Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients

被引:23
作者
Chaher, Nabila [2 ]
Arias-Pulido, Hugo [1 ]
Terki, Nadija [2 ]
Qualls, Clifford [1 ]
Bouzid, Kamel [3 ]
Verschraegen, Claire
Wallace, Anne Marie [4 ]
Royce, Melanie [4 ]
机构
[1] Univ New Mexico, Ctr Canc, Dept Math & Stat, Albuquerque, NM 87131 USA
[2] Ctr Pierre & Marie Curie, Dept Pathol, Algiers, Algeria
[3] Ctr Pierre & Marie Curie, Dept Med Oncol, Algiers, Algeria
[4] Univ New Mexico, Ctr Canc, Dept Internal Med, Albuquerque, NM 87131 USA
关键词
Inflammatory breast cancer; Locally advanced breast cancer; Tumor emboli; Tumor subtypes; Hormone receptors; Growth factor receptors; Overall survival; Disease-free survival; PHASE-II; LAPATINIB MONOTHERAPY; TUNISIA; SURVIVAL; EXPRESSION; DIAGNOSIS; FEATURES; MARKERS; OBESITY; TISSUE;
D O I
10.1007/s10549-011-1422-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Inflammatory breast cancer (IBC) shows a high incidence in Tunisia and Egypt but epidemiological and molecular characteristics have not been described in Algeria. We compared 117 IBC and 59 non-IBC locally advanced breast cancers (LABC), for estrogen and progesterone receptors, HER2, and EGFR protein expression by immunohistochemistry, and HER2 gene amplification by chromogenic in situ hybridization. Demographic, clinico-pathological, and molecular variables were compared with chi-square and Fisher's exact tests to test for significance (P < 0.05, two-tailed). Overall survival (OS) and disease-free survival (DFS) were plotted using Kaplan-Meier curves and compared using the log-rank test. Tumor emboli were detected in 77% of IBC. Palpable masses were found in all LABC but only in 32% of IBC (P < 0.001). Recurrences were higher in LABC than in IBC (48 vs. 35%; P = 0.14) but OS was worse in IBC (68 vs. 71%; P = 0.06). There were no significant differences between IBC and LABC by demographics or by clinico-pathological parameters. The majority of IBC and LABC tumors were luminal A (62 and 64%), followed by basal (similar to 18%, each), triple negative (similar to 18%, each), and HER2+ (similar to 10%, each) subtypes. In multivariate analyses, grade was associated with worse OS (P = 0.04), and DFS (P < 0.001) in IBC; chemo- and radio-therapy were associated with improved OS and DFS, respectively (P < 0.05 for each) in LABC. In conclusion, IBC in Algeria shows similar characteristics to IBC described for Egypt and Tunisia with subtle molecular differences. Current therapeutic treatments were not very effective in this population and new approaches are much needed.
引用
收藏
页码:437 / 444
页数:8
相关论文
共 37 条
[1]
Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors [J].
Arias-Pulido, Hugo ;
Smith, Harriet O. ;
Joste, Nancy E. ;
Bocklage, Therese ;
Qualls, Clifford R. ;
Chavez, Allison ;
Prossnitz, Eric R. ;
Verschraegen, Claire F. .
GYNECOLOGIC ONCOLOGY, 2009, 114 (03) :480-485
[2]
Aziz S A, 2001, Breast J, V7, P398, DOI 10.1046/j.1524-4741.2001.07604.x
[3]
Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin [J].
Ben Hamida, Azza ;
Labidi, Intidhar S. ;
Mrad, Karima ;
Charafe-Jauffret, Emmanuelle ;
Ben Arab, Saida ;
Esterni, Benjamin ;
Xerri, Luc ;
Viens, Patrice ;
Bertucci, Francois ;
Birnbaum, Daniel ;
Jacquemier, Jocelyne .
BMC CANCER, 2008, 8 (1)
[4]
Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer [J].
Boussen, Hamouda ;
Cristofanilli, Massimo ;
Zaks, Tal ;
DeSilvio, Michelle ;
Salazar, Vanessa ;
Spector, Neil .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3248-3255
[5]
Inflammatory Breast Cancer in Tunisia [J].
Boussen, Hamouda ;
Bouzaiene, Hatem ;
Ben Hassouna, Jamel ;
Dhiab, Tarek ;
Khomsi, Fathi ;
Benna, Farouk ;
Gamoudi, Amor ;
Mourali, Nejib ;
Hechiche, Monia ;
Rahal, Khaled ;
Levine, Paul H. .
CANCER, 2010, 116 (11) :2730-2735
[6]
Inflammatory breast cancer and body mass index [J].
Chang, S ;
Buzdar, AU ;
Hursting, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3731-3735
[7]
Inflammatory breast cancer survival: The role of obesity and menopausal status at diagnosis [J].
Chang, S ;
Alderfer, JR ;
Asmar, L ;
Buzdar, AU .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 64 (02) :157-163
[8]
Inflammatory breast cancers in Tunisia and France show similar immunophenotypes [J].
Charafe-Jauffret, Emmanuelle ;
Mrad, Karima ;
Labidl, Sana Intidhar ;
Ben Hamida, Azza ;
Ben Romdhane, Khaled ;
Ben Abdallah, Mansour ;
Ginestier, Christophe ;
Esterni, Benjamin ;
Birnbaum, Daniel ;
Ben Ayed, Farhat ;
Xerri, Luc ;
Viens, Patrice ;
Mezlini, Amet ;
Jacquemier, Jocelyne .
BREAST, 2007, 16 (04) :352-358
[9]
Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature' [J].
Charafe-Jaufrret, E ;
Tarpin, C ;
Bardou, VJ ;
Bertucci, FO ;
Ginestier, C ;
Braud, AC ;
Puig, B ;
Geneix, J ;
Hassoun, J ;
Birnbaum, D ;
Jacquemier, J ;
Viens, P .
JOURNAL OF PATHOLOGY, 2004, 202 (03) :265-273
[10]
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment [J].
Dawood, S. ;
Merajver, S. D. ;
Viens, P. ;
Vermeulen, P. B. ;
Swain, S. M. ;
Buchholz, T. A. ;
Dirix, L. Y. ;
Levine, P. H. ;
Lucci, A. ;
Krishnamurthy, S. ;
Robertson, F. M. ;
Woodward, W. A. ;
Yang, W. T. ;
Ueno, N. T. ;
Cristofanilli, M. .
ANNALS OF ONCOLOGY, 2011, 22 (03) :515-523